Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8395440 | 0.83 | CHRM1 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC7 | |
| SCHEMBL6517414 | 0.81 | TSHR (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3HDAC7 | |
| SCHEMBL28578853 | 0.80 | LMNA (0.58) | TSHRNPSR1LMNAALDH1A1 | |
| SCHEMBL499776 | 0.79 | ALDH1A1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL1302156 | 0.77 | ALDH1A1 (0.39) | TSHRALDH1A1 | |
| Iodide SCHEMBL1301964 | 0.77 | ALDH1A1 (0.39) | TSHRALDH1A1 | |
| Fluoride SCHEMBL1302502 | 0.77 | ALDH1A1 (0.39) | TSHRALDH1A1 | |
| Bromide SCHEMBL1302282 | 0.77 | ALDH1A1 (0.39) | TSHRALDH1A1 | |
| SCHEMBL151180 | 0.75 | TSHR (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL27826451 | 0.74 | MGAM (0.37) | MGAMGAASIMGAM2HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251158-A1 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE | LUNA INNOVATIONS INCORPORATED (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251158-A1 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE | IL1B, IL1A, CD68 | CHRNB2 2331/4885CHRNA4 4087/4885CHRNB4 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.